|
|
Blood, 1 May 2006, Vol. 107, No. 9, pp. 3787-3794.
Prepublished online as a Blood First Edition Paper on January 17, 2006; DOI 10.1182/blood-2005-11-4495.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response
Alejo Chorny,
Elena Gonzalez-Rey,
Amelia Fernandez-Martin,
Doina Ganea, and
Mario Delgado
From the Institute of Parasitology and Biomedicine, Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain; and Department of Biological Sciences, Rutgers University, Newark, NJ.
Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation (BMT) for the treatment of leukemia and other immunogenetic disorders. The use of tolerogenic dendritic cells (DCs) that induce the generation/activation of regulatory T (Tr) cells for the treatment of acute GVHD following allogeneic BMT has been recently established. Therefore, the identification of factors that contribute to the development of tolerogenic DCs is highly relevant. We report on the use of the known immunosuppressive neuropeptide, the vasoactive intestinal peptide (VIP), as a new approach to induce tolerogenic DCs with the capacity to prevent acute GVHD. DCs differentiated in the presence of VIP impair allogeneic haplotype-specific responses of donor CD4+ cells in mice given transplants by inducing the generation of Tr cells in the graft. VIP-induced tolerogenic DCs did not abrogate the graft-versus-leukemia response presumably by not affecting the cytotoxicity of transplanted T cells against the leukemic cells. Therefore, the inclusion of VIP-induced tolerogenic DCs in future therapeutic regimens may minimize the dependence on nonspecific immunosuppressive drugs used currently as antirejection therapy, and facilitate the successful transplantation from mismatched donors, by reducing the deleterious consequences of acute GVHD and extending the applicability of BMT.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Dendritic cells get VIP treatment
- Edmund K. Waller
Blood 2006 107: 3423-3424.
[Full Text]
[PDF]
-
Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells
- Elena Gonzalez-Rey, Alejo Chorny, Amelia Fernandez-Martin, Doina Ganea, and Mario Delgado
Blood 2006 107: 3632-3638.
[Abstract]
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. E. Anderson, B. L. Sayers, M. A. Haniffa, D. J. Swan, J. Diboll, X.-N. Wang, J. D. Isaacs, and C. M. U. Hilkens
Differential regulation of naive and memory CD4+ T cells by alternatively activated dendritic cells
J. Leukoc. Biol.,
July 1, 2008;
84(1):
124 - 133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fujita, Y. Sato, K. Sato, K. Eizumi, T. Fukaya, M. Kubo, N. Yamashita, and K. Sato
Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells
Blood,
November 15, 2007;
110(10):
3793 - 3803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fabricius, M. S. O'Dorisio, S. Blackwell, and B. Jahrsdorfer
Human Plasmacytoid Dendritic Cell Function: Inhibition of IFN-{alpha} Secretion and Modulation of Immune Phenotype by Vasoactive Intestinal Peptide
J. Immunol.,
November 1, 2006;
177(9):
5920 - 5927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rutella, S. Danese, and G. Leone
Tolerogenic dendritic cells: cytokine modulation comes of age
Blood,
September 1, 2006;
108(5):
1435 - 1440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. K. Waller
A tale of two T cells: suppressor CD8 T cells recalled to life
Blood,
June 1, 2006;
107(11):
4203 - 4204.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gonzalez-Rey, A. Chorny, A. Fernandez-Martin, D. Ganea, and M. Delgado
Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells
Blood,
May 1, 2006;
107(9):
3632 - 3638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
